Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXO-CD24 in Mild-Moderate ARDS
NCT05947747Phase 2Recruiting
- Sponsor
- Nano24
- Start
- Jul 2023
- Primary completion
- Dec 2025
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of exosomes overexpressing CD24 in acute respiratory distress syndrome (ARDS), sponsored by Nano24. Started Jul 2023; status: recruiting.
02
Drugs
exosomes overexpressing CD24
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT05947747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05947747.